NASDAQ:ALVR Allovir Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Allovir Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $28.24 +2.21 (+8.49 %) (As of 09/25/2020 11:44 AM ET) Add Compare Share Today's Range$24.60Now: $28.24▼$28.4750-Day Range$21.05MA: $30.25▼$42.7052-Week Range$18.15Now: $28.24▼$45.28Volume9,129 shsAverage Volume451,852 shsMarket Capitalization$609.28 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsChartCompetitorsEarningsInsider TradesHeadlinesSocial Media Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is Viralym-M, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. Its preclinical and clinical development product candidates include ALVR106 for respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108 to treat human herpesvirus-8, including Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's diseases. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingAllovir has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $46.67, Allovir has a forecasted upside of 67.8% from its current price of $27.81.Amount of Analyst CoverageAllovir has only been the subject of 4 research reports in the past 90 days. Previous Next 0.0 Community Rank Outperform VotesAllovir has received 4 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAllovir has received 0 “underperform” votes. (Add your “underperform” vote.)MarketBeat's community ratings are surveys of what our community members think about Allovir and other stocks. Vote “Outperform” if you believe ALVR will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ALVR will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAllovir does not currently pay a dividend.Dividend GrowthAllovir does not have a long track record of dividend growth. Previous Next 3.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Allovir insiders have bought more of their company's stock than they have sold. Specifically, they have bought $158,100.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 1.00% of the stock of Allovir is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Allovir are expected to grow in the coming year, from ($1.66) to ($1.44) per share. Previous Next Analyst Opinion: 3.5Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.43 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ALVR Previous Symbol CUSIPN/A CIKN/A Webwww.allovir.com Phone617-433-2605Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees20 Outstanding Shares21,575,000Market Cap$609.28 million Next Earnings Date12/2/2020 (Estimated) OptionableNot Optionable $28.24 +2.21 (+8.49 %) (As of 09/25/2020 11:44 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive ALVR News and Ratings via Email Sign-up to receive the latest news and ratings for ALVR and its competitors with MarketBeat's FREE daily newsletter. Allovir (NASDAQ:ALVR) Frequently Asked Questions Do Wall Street analysts recommend investors buy shares of Allovir? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allovir in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Allovir. When is Allovir's next earnings date? Allovir is scheduled to release its next quarterly earnings announcement on Wednesday, December 2nd 2020. View our earnings forecast for Allovir. How were Allovir's earnings last quarter? Allovir (NASDAQ:ALVR) released its quarterly earnings data on Wednesday, September, 2nd. The company reported ($4.43) EPS for the quarter, missing analysts' consensus estimates of ($0.31) by $4.12. View Allovir's earnings history. What price target have analysts set for ALVR? 4 Wall Street analysts have issued 1 year price targets for Allovir's stock. Their forecasts range from $41.00 to $50.00. On average, they anticipate Allovir's stock price to reach $46.67 in the next year. This suggests a possible upside of 65.3% from the stock's current price. View analysts' price targets for Allovir. Who are some of Allovir's key competitors? Some companies that are related to Allovir include Sorrento Therapeutics (SRNE), Revolution Medicines (RVMD), Mesoblast (MESO), SpringWorks Therapeutics (SWTX), BAVARIAN NORDIC/S (BVNRY), Editas Medicine (EDIT), Forma Therapeutics (FMTX), NanoString Technologies (NSTG), Cortexyme (CRTX), Sangamo Therapeutics (SGMO), Beam Therapeutics (BEAM), Kymera Therapeutics (KYMR), Coherus Biosciences (CHRS), Compugen (CGEN) and Regenxbio (RGNX). View all competitors. What other stocks do shareholders of Allovir own? Based on aggregate information from My MarketBeat watchlists, some companies that other Allovir investors own include Johnson & Johnson (JNJ), Coca-Cola (KO), Regeneron Pharmaceuticals (REGN), Axon Enterprise (AAXN), Abbott Laboratories (ABT), Appian (APPN), Alteryx (AYX), Boeing (BA), Biohaven Pharmaceutical (BHVN) and Carnival (CCL). Who are Allovir's key executives? Allovir's management team includes the following people: Mr. David L. Hallal, Chairman & CEO (Age 54)Mr. Vikas Sinha, Pres, CFO & Director (Age 57)Mr. Brett R. Hagen, Chief Accounting Officer (Age 47)Dr. Ann M. Leen Ph.D., Chief Scientific Officer (Age 44)Mr. Edward Miller, Gen. Counsel (Age 55) When did Allovir IPO? (ALVR) raised $252 million in an initial public offering on Thursday, July 30th 2020. The company issued 14,800,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, J.P. Morgan, SVB Leerink and Piper Sandler served as the underwriters for the IPO. What is Allovir's stock symbol? Allovir trades on the NASDAQ under the ticker symbol "ALVR." When did Allovir's quiet period expire? Allovir's quiet period expired on Tuesday, September 8th. Allovir had issued 16,250,000 shares in its IPO on July 30th. The total size of the offering was $276,250,000 based on an initial share price of $17.00. During Allovir's quiet period, insiders and underwriters that worked on the IPO were prevented from issuing any research reports or earnings estimates for the company because of SEC regulations. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company. How do I buy shares of Allovir? Shares of ALVR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Allovir's stock price today? One share of ALVR stock can currently be purchased for approximately $28.24. How big of a company is Allovir? Allovir has a market capitalization of $609.28 million. Allovir employs 20 workers across the globe. What is Allovir's official website? The official website for Allovir is www.allovir.com. How can I contact Allovir? Allovir's mailing address is 139 MAIN STREET SUITE 500, CAMBRIDGE MA, 02142. The company can be reached via phone at 617-433-2605 or via email at [email protected] This page was last updated on 9/25/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
